Rasagiline shows promise in treating negative symptoms of schizophrenia
Results of a new study involving 60 patients with schizophrenia support additional research into the potential benefits of the monoamine oxidase inhibitor (MAOI) rasagiline in addressing troubling negative symptoms of the illness. The most pronounced effect seen from rasagiline was on avolition, a l...
Gespeichert in:
Veröffentlicht in: | Psychopharmacology update 2015-06, Vol.26 (6), p.1-6 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Results of a new study involving 60 patients with schizophrenia support additional research into the potential benefits of the monoamine oxidase inhibitor (MAOI) rasagiline in addressing troubling negative symptoms of the illness. The most pronounced effect seen from rasagiline was on avolition, a lack of drive to pursue goals that is highly associated with functional impairment in patients with schizophrenia. Study results were published online Nov. 2, 2014, in Schizophrenia Bulletin. |
---|---|
ISSN: | 1068-5308 1556-7532 |
DOI: | 10.1002/pu.30050 |